Gambi Francesco, De Berardis Domenico, Campanella Daniela, Carano Alessandro, Sepede Gianna, Salini Gabriele, Mezzano Daniela, Cicconetti Alessandra, Penna Laura, Salerno Rosa Maria, Ferro Filippo Maria
Department of Oncology and Neurosciences, Institute of Psychiatry, University 'G. D'Annunzio' of Chieti, Chieti, Italy.
J Psychopharmacol. 2005 Sep;19(5):483-7. doi: 10.1177/0269881105056527.
We investigated the efficacy of mirtazapine in the treatment of generalized anxiety disorder (GAD). Forty-four adult outpatients with GAD were treated openly with a fixed dose of mirtazapine (30 mg) for 12 weeks. The primary outcome measure was the change from baseline in total score on the Hamilton Rating Scale for Anxiety (HAM-A). The Clinical Global Impression of Improvement (CGI-I) was rated at the endpoint. Patients with a reduction of 50% or more on the HAM-A total score and a CGI-I score of 1 or 2 at endpoint were considered responders to treatment; remission was defined as a HAM-A score <or=7. At 12 weeks, response was achieved by 79.5% of the patients (n=35) and remission by 36.4% of patients (n=16). This study supports the notion that mirtazapine is an efficacious and well tolerated treatment for GAD. Limitations of the present study must be considered and further placebo-controlled trials are needed.
我们研究了米氮平治疗广泛性焦虑症（GAD）的疗效。44例成年GAD门诊患者接受了为期12周的固定剂量米氮平（30毫克）开放治疗。主要结局指标是汉密尔顿焦虑量表（HAM - A）总分相对于基线的变化。在研究终点对临床总体印象改善量表（CGI - I）进行评分。HAM - A总分降低50%或更多且终点时CGI - I评分为1或2的患者被视为治疗有效者；缓解定义为HAM - A评分≤7。12周时，79.5%的患者（n = 35）达到有效，36.4%的患者（n = 16）达到缓解。本研究支持米氮平是一种治疗GAD有效且耐受性良好的药物这一观点。必须考虑本研究的局限性，还需要进一步的安慰剂对照试验。
